Search papers, labs, and topics across Lattice.
This review article discusses the role of the CD40-CD40L costimulatory pathway in autoimmune pathogenesis, highlighting how enhanced signaling promotes autoreactive B cell activation and autoantibody production. Early clinical trials of anti-CD40L monoclonal antibodies in lupus faced setbacks due to thrombotic events, leading to the development of novel Fc-silent anti-CD40L antibodies and anti-CD40 antibodies. These new-generation antagonists have shown promising results in phase 2 trials, renewing interest in therapeutic blockade of this pathway.
Next-generation CD40L and CD40 antagonists offer a potentially safer and more effective approach to managing B cell-driven autoimmune diseases by overcoming the safety concerns associated with first-generation anti-CD40L antibodies.
PURPOSE OF REVIEW CD40 ligand (CD40L, CD154) is a costimulatory molecule required for adaptive immune responses. It arms CD4+ T cells to provide critical "help" to B cells, dendritic cells, and other antigen-presenting cells through interactions with CD40. Enhanced CD40L signaling promotes autoreactive B cell activation, germinal center hyperactivity, and autoantibody production, processes central to autoimmune pathogenesis. Recognition of the pathway's importance in autoimmunity prompted clinical trials of anti-CD40L monoclonal antibodies in lupus, but early enthusiasm faded after unexpected thrombotic events. These first generation anti-CD40L antibodies were later found to trigger platelet activation through an Fc-mediated mechanism and led to re-engineering of antagonist therapeutic proteins. RECENT FINDINGS Preclinical studies confirm that CD40L inhibition ameliorates disease across diverse autoimmune models by restraining aberrant B-cell and T-cell responses. Novel Fc-silent anti-CD40L antibodies, nonantibody CD40L antagonists, and anti-CD40 antibodies have since been developed to overcome prior safety concerns. These new-generation CD40L and CD40 antagonists have shown promising results in phase 2 trials spanning multiple autoimmune settings, renewing interest in therapeutic blockade of this pathway. SUMMARY Next-generation CD40L and CD40-directed therapies are redefining costimulatory blockade in autoimmunity. Integrating preclinical discoveries with clinical translation offers new opportunities to optimize treatment and transform management of B cell-driven autoimmune disease.
